Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 51, Issue 2, 2013, Pages 132-140

  Macha, Sreeraj ^a   Dieterich, Sabine ^b   Mattheus, Michaela ^b   Seman, Leo J ^a   Broedl, Uli C ^b   Woerle, Hans J ^b  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Drug drug interaction; Empagliflozin; Metformin; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

EMPAGLIFLOZIN; METFORMIN;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DATA ANALYSIS SOFTWARE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BENZHYDRYL COMPOUNDS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; REFERENCE VALUES; YOUNG ADULT;

EID: 84873849619     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201794     Document Type: Article

References (16)

1. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009; 122: 443-453. doi:10.1016/j.amjmed.2008.09.047 PubMed
2. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care. 2006; 29: 531-537. doi:10.2337/diacare.29.03.06.dc05-1254 PubMed
3. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999; 281: 2005-2012. doi:10.1001/jama.281.21.2005 PubMed
4. Mather A, Pollock C. Glucose handling by the kidney. Kidney Int Suppl. 2011; 79: S1-S6. doi:10.1038/ki.2010.509 PubMed
5. Heise T, Seewaldt-Becker E, Macha S, Hantel S, Huber K, Pinnetti S, Seman L, Woerle H-J. BI 10773, a sodium-glucose co-transporter inhibitor (SGLT-2), is safe and efficacious following 4-week treatment in patients with type 2 diabetes. Diabetes. 2010; 59 (Suppl 1): A172 [629-P].
6. Thomas L, Grempler R, Eckhardt M, Himmelsbach F, Sauer A, Klein T, Eickelmann P, Mark M. Longterm treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obes Metab. 2012; 14: 94-96. doi:10.1111/j.1463-1326.2011.01518.x PubMed
7. Port A, Macha S, Seman L, Nehmiz G, Simons G, Koegel A, Harder D, Ren B, Iovino M, Pinnetti S, Dugi K. Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 10773, a sodium glucose cotransporter-2 (SGLT-2), in healthy volunteers. Diabetes. 2010; 59 (Suppl 1): A155 [569-P].
8. International Diabetes Federation Clinical Guidelines Taskforce. Global guideline for type II diabetes. 2005 http://www.idf.org/webdata/docs/ IDF%20GGT2D.pdf. Accessed 23 May 2012.
9. Green J, Feinglos M. New combination treatments in the management of diabetes: focus on sitagliptin-metformin. Vasc Health Risk Manag. 2008; 4: 743-751. PubMed
10. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011; 50: 81-98. doi:10.2165/11534750-000000000-00000 PubMed
11. Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan Rao C, Madhusudan Rao Y. Effect of cephalexin on the pharmacokinetics of metformin in healthy human volunteers. Drug Metabol Drug Interact. 2002; 19: 41-48. doi:10.1515/DMDI.2002.19.1.41 PubMed
12. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol. 1987; 23: 545-551. doi:10.1111/j.1365-2125.1987. tb03090.x PubMed
13. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf. 2005; 28: 601-631. doi:10.2165/00002018-200528070-00004 PubMed
14. Seman L, Macha S, Jones P, Marquart A, Port A, Pinnetti S, Heise T, Dugi K. Safety and tolerability of BI 10773, a sodium-glucose co-transporter (SGLT-2) inhibitor, following 8-days treatment in patients with Type 2 diabetes. Diabetes. 2010; 59 (Suppl 1): A156 [571-P].
15. Kipnes M. Sodium-glucose cotransporter 2 inhibitors in the treatment of type 2 diabetes: a review of Phase II and III trials. Clin Investig. 2011; 1: 145-156. doi:10.4155/cli.10.12
16. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005; 20: 379-386. doi:10.2133/dmpk.20.379 PubMed